fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy .
modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change .
a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care . this short communication presents the results for patients enrolled from abu dhabi .
please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail .
the patient characteristics for the entire cohort divided as insulin - nave and insulin users is shown in the table 1 .
other groups were insulin aspart ( n = 13 ) , basal insulin plus insulin aspart ( n = 42 ) , biphasic insulin aspart ( n = 134 ) and other insulin combinations ( n = 41 ) . after 24 weeks of treatment , overall hypoglycaemic events reduced from 2.0 events / patient - year to 0.2 events / patient - year in insulin user group whereas hypoglycaemia increased from 0.1 events / patient - year to 0.5 events / patient - year in insulin naive group . however , this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline .
major hypoglycaemic events remained same as that of baseline ( 0.1 events / patient - year ) in insulin nave group whereas it reduced from 0.1 events / patient - year to 0.0 events / patient - year in insulin users .
blood pressure decreased and overall lipid profile improved at week 24 in the cohort [ tables 2 and 3 ] .
overall demographic data all parameters of glycaemic control improved from baseline to study end in the total cohort .
more than one third of patients achieved hba1c < 7.0% at week 24 [ table 4 ] .
overall efficacy data of the total cohort , 134 patients started on biphasic insulin aspart  ogld , of which 84 ( 62.7% ) were insulin nave and 50 ( 37.3% ) were insulin users .
after 24 weeks of starting or switching to biphasic insulin aspart , hypoglycaemic events increased from 0.2 events / patient - year to 0.8 events / patient - year in insulin nave group and from 0.5 events / patient - year to 0.6 events / patient - year in insulin users group . a small increase in body weight
was also observed at the end of the study [ tables 5 and 6 ] .
biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] .
biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 42 patients started on basal + insulin aspart  ogld , of which 11 ( 26.2% ) were insulin nave and 31 ( 73.8% ) were insulin users .
after 24 weeks of starting or switching to basal + insulin aspart , hypoglycaemic events reduced from 4.6 events / patient - year to 0.0 events / patient - year in insulin user group whereas hypoglycaemia was nil similar to baseline in insulin nave group .
body weight decreased at the end of the study [ tables 8 and 9 ] .
basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] .
basal+insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 152 patients started on insulin detemir  ogld , of which 99 ( 65.1% ) were insulin nave and 53 ( 34.9% ) were insulin users .
after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events reduced from 2.7 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia increased from 0.0 events / patient - year to 0.3 events / patient - year in insulin nave group .
a decrease in body was also observed at 24 weeks [ tables 11 and 12 ] .
insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] .
insulin detemiroral glucose - lowering drug efficacy data of the total cohort , 13 patients started on insulin aspart  ogld , of which 5 ( 38.5% ) were insulin nave and 8 ( 61.5% ) were insulin users .
after 24 weeks of starting or switching to insulin aspart , hypoglycaemia was nil similar to that of baseline for both insulin nave and insulin user groups .
a decrease in body weight was observed in insulin nave group [ tables 14 and 15 ] .
insulin aspartoral glucose - lowering drug safety data mean hba1c and fpg values improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for both insulin nave and insulin user groups [ table 16 ] .
of the total cohort , 134 patients started on biphasic insulin aspart  ogld , of which 84 ( 62.7% ) were insulin nave and 50 ( 37.3% ) were insulin users .
after 24 weeks of starting or switching to biphasic insulin aspart , hypoglycaemic events increased from 0.2 events / patient - year to 0.8 events / patient - year in insulin nave group and from 0.5 events / patient - year to 0.6 events / patient - year in insulin users group . a small increase in body weight
was also observed at the end of the study [ tables 5 and 6 ] .
biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] .
of the total cohort , 42 patients started on basal + insulin aspart  ogld , of which 11 ( 26.2% ) were insulin nave and 31 ( 73.8% ) were insulin users .
after 24 weeks of starting or switching to basal + insulin aspart , hypoglycaemic events reduced from 4.6 events / patient - year to 0.0 events / patient - year in insulin user group whereas hypoglycaemia was nil similar to baseline in insulin nave group .
body weight decreased at the end of the study [ tables 8 and 9 ] .
basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] .
of the total cohort , 152 patients started on insulin detemir  ogld , of which 99 ( 65.1% ) were insulin nave and 53 ( 34.9% ) were insulin users .
after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events reduced from 2.7 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia increased from 0.0 events / patient - year to 0.3 events / patient - year in insulin nave group .
a decrease in body was also observed at 24 weeks [ tables 11 and 12 ] .
insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] . insulin detemiroral glucose - lowering drug efficacy data
of the total cohort , 13 patients started on insulin aspart  ogld , of which 5 ( 38.5% ) were insulin nave and 8 ( 61.5% ) were insulin users .
after 24 weeks of starting or switching to insulin aspart , hypoglycaemia was nil similar to that of baseline for both insulin nave and insulin user groups .
a decrease in body weight was observed in insulin nave group [ tables 14 and 15 ] .
insulin aspartoral glucose - lowering drug safety data mean hba1c and fpg values improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for both insulin nave and insulin user groups [ table 16 ] .
our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; basal + insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld .
major hypoglycaemic events remained same as that of baseline ( 0.1 events / patient - year ) in insulin nave group whereas major hypoglycaemia reduced from 0.1 events / patient - year to 0.0 events / patient - year in insulin users .
though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in abu dhabi .
 background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66,726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from abu dhabi.results:a total of 383 patients were enrolled in the study . 
 four different insulin analogue regimens were used in the study . 
 study patients had started on or were switched to biphasic insulin aspart ( n = 134 ) , insulin detemir ( n = 152 ) , insulin aspart ( n = 13 ) , basal insulin plus insulin aspart ( n = 42 ) and other insulin combinations ( n = 41 ) . at baseline 
 glycaemic control was poor for both insulin nave ( mean hba1c : 9.4% ) and insulin user ( mean hba1c : 9.1% ) groups . after 24 weeks of treatment , both groups showed improvement in hba1c ( insulin nave : 2.1% , insulin users : 1.8% ) . 
 sadrs did not occur in any of the study patients . 
 major hypoglycaemic events remained same as that of baseline ( 0.1 events / patient - year ) for insulin nave group whereas major hypoglycaemia reduced from 0.1 events / patient - year to 0.0 events / patient - year in insulin users.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia . 
I
M
R
Biphasic insulin aspart  OGLD
Basal + insulin aspart  OGLD
Insulin detemir  OGLD
Insulin aspart  OGLD
C